Genetic susceptibility and skin irritability

Genetic susceptibility and skin irritability - Genetic susceptibility and skin irritability

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33753

Enrollment

100

Registered

2009-07-16

Start date

2009-09-07

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Filaggrin mutation polymorphism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Written informed consent Age 18 to 70 Legally competent adults Inclusion in fragrance study

Exclusion criteria

Exclusion criteria: Severe illness, defined as life threatenig of severely disabling

Design outcomes

Primary

Measure	Time frame
The study parameters are: Objective 1&2: -Mean patch test reactions on SLS in 0%, 0.45%, 0.67%, 1% and 1.5% in water solution in TEWL (derived from fragrance study) This is a continuous numerical data. Objective 3 &4: -ACD The endpoints are: -Presence or absence of a mutation for fillagrin and/or specific cytokines (such as interleukin (IL)-1, IL-1, IL-8, IL-10, and eventually other relevant cytokines, dependent on future developments) -Atopy scoring through questionnaires -Demographic data of the population (gender, age, etc.)	—

Measure

Time frame

The study parameters are: Objective 1&2: -Mean patch test reactions on SLS in 0%, 0.45%, 0.67%, 1% and 1.5% in water solution in TEWL (derived from *fragrance study*) This is a continuous numerical data. Objective 3 &4: -ACD The endpoints are: -Presence or absence of a mutation for fillagrin and/or specific cytokines (such as interleukin (IL)-1*, IL-1*, IL-8, IL-10, and eventually other relevant cytokines, dependent on future developments) -Atopy scoring through questionnaires -Demographic data of the population (gender, age, etc.)

—

Countries

Netherlands

Outcome results